Betapace

indicated to manage ventricular and supraventricular arrhythmias to mitigate the risk of life-threatening heart rhythm irregularities.

Strengths: 40mg

Medicine details

Alternative names

Sotacor

Therapeutic class

Class III Antiarrhythmic

Pharmacological class

Non-selective Beta-blocker

Minor side effects

fatigue; dizziness; headache

Moderate side effects

bradycardia; dyspnoea; nausea

Dosage forms

Tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Bristol-Myers Squibb

Onset Time

1–2 hours

Duration

12–24 hours

Storage instructions

Store at room temperature.

Drug interactions

amiodarone; diuretics; calcium channel blockers

Age restrictions

Use with caution in children.

Pregnancy and breastfeeding

Pregnancy caution advised. Avoid during breastfeeding.

Contraindications

asthma; bradycardia; second or third degree heart block; uncompensated heart failure

Precautions and warnings

regular ecg monitoring required; electrolyte imbalance must be corrected before treatment

Serious side effects

torsade de pointes — requires immediate medical attention; heart block — requires immediate medical attention

Patient summary

indicated to manage ventricular and supraventricular arrhythmias to mitigate the risk of life-threatening heart rhythm irregularities.

Mechanism of action

Sotalol acts as a non-selective beta-adrenoreceptor antagonist and also exhibits Class III antiarrhythmic properties by prolonging the cardiac action potential, which helps stabilize heart rhythm.

Betapace

indicated to manage ventricular and supraventricular arrhythmias to mitigate the risk of life-threatening heart rhythm irregularities.

Editorial Notes

  • Active ingredient(s): Sotalol
  • Listed indication(s): Ventricular Arrhythmias, Atrial Fibrillation

Available option

  • 120 tablets - 40 mg16-40-mg-2251